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A B S T R A C T
Background: Infection with the inﬂuenza A virus can cause severe disease and mortality. The effect of the
different subtypes of inﬂuenza on morbidity and mortality is not yet known in Turkey. The aim of this
study was to describe the predictors of fatality related to inﬂuenza A infection among hospitalized
patients in Istanbul during the 2015–2016 inﬂuenza season, and to detail the differences between
infections caused by H3N2 and H1N1.
Methods: This was a multicenter study performed by the Istanbul Respiratory Infections Study Group of The
Turkish Society of Clinical Microbiology and Infectious Diseases (KL_IM_IK), among patients hospitalized for
inﬂuenza in Istanbul during the 2015–2016 inﬂuenza season.
Results: A total of 222 patients hospitalized with laboratory-conﬁrmed inﬂuenza during the 2015–2016
seasonwere included in the study, of whom 25 (11.2%)died. The fatality ratewas signiﬁcantly higheramong
patients older than 65 years of age and those with chronic heart and kidney diseases (p < 0.001), chronic
neurological diseases (p = 0.009), and malignancies (p = 0.021). Thrombocyte counts were lower in those
who died than in those who survived (p < 0.004). The median alanine aminotransferase, aspartate
aminotransferase, lactate dehydrogenase, creatinine phosphokinase, and C-reactive protein levels were
higher among fatal cases. In the multivariate analysis for the prediction of fatality, being >65 years old
(odds ratio (OR) 6.9, 95% conﬁdence interval (CI) 2.07–23.08, p = 0.002), being infected with inﬂuenza A
(H3N2) (OR 4.2, 95% CI 1.27–14.38, p = 0.019), and a 1-day delay in antiviral use (OR 1.28, 95% CI 1.01–1.63,
p = 0.036) were found to be associated with an increased likelihood of fatality.
Conclusions: The case fatality rate of inﬂuenza A(H3N2) was signiﬁcantly higher than that of inﬂuenza A
(H1N1). Detection of the infection, allowing the opportunity for the early use of antiviral agents, was found
to be important for the prevention of fatality. The vaccination should be prioritized for at-risk groups.
© 2019 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Inﬂuenza is an acute viral infection with a clinical range from
self-limiting respiratory symptoms characterized by fever, cough,
and headache in healthy individuals to complications such as
bronchitis, acute otitis media, secondary bacterial pneumonia,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
d Library from ClinicalKey.com.au by Elsevier on August 08, 2019.
ion. Copyright ©2019. Elsevier Inc. All rights reserved.
Table 1
Demographic characteristics of the patients infected with inﬂuenza A and their risk
factors for mortality.
Died
n = 25,
n (%)
Survived
n = 197,
n (%)
p-Value
Sex, female 10 (40) 116 (59) 0.073
Age (years), mean  SD 65  22 36  26 <0.001
Age 65 14 (56) 33 (17) <0.001
Age 16 0 (0) 58 0.002
Obese 1 (4) 13 (7) 0.615
Pregnant women 1 (5) 6 (5) 0.939
Comorbid chronic diseases
Chronic heart disease 9 (36) 19 (10) <0.001
Diabetes mellitus 5 (24) 23 (12) 0.085
Chronic renal disease 6 (24) 8 (4) <0.001
Chronic neurological disease 5 (20) 11 (6) 0.009
Chronic obstructive lung disease 3 (12) 24 (12) 0.979
Malignancy 5 (20) 13 (7) 0.021
Vaccinated 0 4 (2) 0.472
Laboratory ﬁndings
Leukocyte count (109/l), median 5.84 7.39 0.146
Thrombocyte count (109/l), median 123 197 0.004
AST (U/l), median 112 34 <0.001
ALT (U/l), median 44 27 <0.001
CPK (mg/l), median 239 120 0.001
LDH (IU/l), median 478 320 0.025
CRP (mg/l), median 91 22 0.004
Inﬂuenza A H3N2 13 (54) 39 (21) <0.001
Inﬂuenza A H1N1 11 (45) 144 (79) <0.001
Chest X-ray ﬁndings
Lobar 2 (8) 9 (5) 0.456
Interstitial 11 (44) 44 (22) 0.018
Bilateral involvement 17 (71) 52 (39) <0.001
Days to starting oseltamivir after
disease onset, mean  SD
4  3 2.6  2 0.025
Secondary bacterial infection 3 (12) 7 (4) 0.055
Days from onset to hospital
admission, mean
3.8 2.7 0.04
ICU stay 20 (80) 20 (10) <0.001
Use of invasive mechanical ventilation 17 (94) 12 (11) <0.001
Use of non-invasive mechanical
ventilation
6 (33) 15 (13) 0.023
Length of hospital stay (days),
mean  SD
7  6 8  10 0.664
Antibiotic use 18 (78) 122 (64) 0.171
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine
phosphokinase; CRP, C-reactive protein; ICU, intensive care unit; LDH, lactate
dehydrogenase; SD, standard deviation.
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patients with chronic diseases (Reed et al., 2015). It is usually
diagnosed clinically on the basis of characteristic symptoms and
seasonal epidemiology (Treanor, 2015). Early antiviral treatment
(oseltamivir or zanamivir) is recommended for patients at risk of
complications (Louie et al., 2012). Some studies have reported
that a higher proportion of hospitalized patients with severe
disease during the 2010–2011 season had inﬂuenza A(H1N1)
(Lehners et al., 2013; Chaves et al., 2013), but it remains unclear
which inﬂuenza virus types and subtypes are more virulent. In
another study, the authors suggested that hospitalized patients
with inﬂuenza A(H1N1) were younger and developed more
respiratory complications, acute respiratory distress syndrome
(ARDS), and septic shock than patients with inﬂuenza A(H3N2)
(Minchole et al., 2016).
Based on the authors’ experience of the A(H1N1)pdm outbreak
in Turkey (Ergonul et al., 2014), the aim of the present study was to
describe the predictors of fatality related to inﬂuenza A infection
among hospitalized patients in 11 different hospitals in Istanbul
during the 2015–2016 inﬂuenza season, and to determine the
differences in morbidity and mortality according to the inﬂuenza
virus subtypes.
Methods
Study population
The study was performed by the Istanbul Respiratory Infections
Study Group of The Turkish Society of Clinical Microbiology and
Infectious Diseases (KL_IM_IK). Patients who were hospitalized for
an inﬂuenza-like illness (ILI) in Istanbul during the 2015–2016
inﬂuenza season and who were positive for inﬂuenza A by PCR
were included. The largest 11 hospitals in Istanbul participated in
the study. Three of these hospitals are university hospitals and
eight are training and research hospitals of the Ministry of Health
of Turkey. Patients who were diagnosed with inﬂuenza B and
inﬂuenza A by rapid antigen test (ELISA) were excluded.
A case of inﬂuenza-associated hospitalization was deﬁned as a
person who was admitted with suspected inﬂuenza and who
presented at least one of the Infectious Diseases Society of America
(IDSA) conditions (Harper et al., 2009) and had a positive PCR test.
Oseltamivir was initiated before PCR results were obtained,
within 24 h after admission. If the results of PCR were negative,
then oseltamivir was withdrawn. In positive cases, antiviral
therapy was continued for at least 5 days at the usual dose.
Statistical analysis
In the univariate analysis, comparing patients who died and
those who survived, categorical data were tested by Chi-square test
and the means of the two groups were compared by t-test (Tables 1
and 2). Parameters found to be statistically signiﬁcant in the
univariate analysis were tested by logistic regression to predict the
risk of fatality (Table 3). The independent variables included in the
model were age >65 years, detection of inﬂuenza A(H3N2) versus
inﬂuenza A(H1N1), early use of neuraminidase inhibitors, second-
ary bacterial infection, and having a malignant disease. Stata
version 11 software (StataCorp, College Station, TX, USA) was used
for the statistical analysis, and statistical signiﬁcance was set at
p < 0.05.
Results
A total of 222 patients hospitalized in the 11 hospitals with
laboratory-conﬁrmed inﬂuenza during the 2015–2016 season
were included in the study. The population of Istanbul in theDownloaded for Anonymous User (n/a) at University of Queensland Lib
For personal use only. No other uses without permission. C2016 census was 14 800 000 (http://www.tuik.gov.tr), and
during the 2015–2016 season, inﬂuenza A virus was detected
in 2196 out of 5509 samples (40%). The inﬂuenza attack rate was
14.8/100 000 (2196/14 800 000). The hospitalization rate for
inﬂuenza A in the population was 1.4/100 000 (222/14 800 000),
and 10% (222/2196) among the diagnosed patients.
The mean age of the 222 patients hospitalized with inﬂuenza A
was 39 years (standard deviation (SD) 27 years); 47 patients (21%)
were older than 65 years. One hundred and twenty-six patients
(57%) were female. Among the hospitalized patients, 25 (11.2%)
died. Thirteen of the 25 fatal cases (54%) had inﬂuenza A(H3N2)
and 11 (45%) had inﬂuenza A(H1N1); the virus was untyped for one
patient (p < 0.001). There were no deaths under age 16 years. The
mean age of the patients who died was 65 years; the mean age of
those who survived was 36 years (p < 0.001) (Table 1). The fatality
rate was signiﬁcantly higher among patients with chronic heart
and kidney diseases (p < 0.001), chronic neurological diseases
(p = 0.009), and malignancies (p = 0.021) (Table 1).
Among the study patients, 115 (69.6%) were infected with
inﬂuenza A(H1N1) and 52 (23.4%) with inﬂuenza A(H3N2); the
virus was untyped for 15 inﬂuenza A virus-infected patients.
Compared to patients with inﬂuenza A(H3N2), patients withrary from ClinicalKey.com.au by Elsevier on August 08, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
Table 2
Comparison of the characteristics of patients with a diagnosis of inﬂuenza
between those with H1N1 and those with H3N2.
H1N1
n = 155,
n (%)
H3N2
n = 52,
n (%)
p-Value
Sex, female 84 (54) 31 (60) 0.496
Age (years), mean  SD 35  25 47  30 0.005
Age 65 25 (16) 18 (35) 0.004
Age 16 45 (29) 13 (25) 0.575
Morbidly obese 8 (5) 3 (6) 0.866
Pregnant women 3 (3) 2 (6) 0.358
Comorbid chronic diseases
Chronic heart disease 17 (11) 11 (21) 0.063
Diabetes mellitus 19 (12) 7 (13) 0.821
Chronic renal disease 7 (5) 7 (13) 0.026
Chronic neurological disease 12 (8) 4 (8) 0.991
Chronic obstructive lung disease 19 (12) 5 (10) 0.607
Malignancy 8 (5) 5 (10) 0.252
Vaccinated 2 (4) 2
(0.37)
0.247
Laboratory ﬁndings
Leukocyte count (109/l), median 7.25 6.60 0.201
Thrombocyte count (109/l), median 188.0 191.5 0.973
AST (U/l), median 42 38 0.547
ALT (U/l), median 27 32 0.480
CPK (mg/l), median 123 166 0.113
LDH (IU/l), median 316 309 0.468
CRP (mg/l), median 22 22 0.467
Chest X-ray ﬁndings
Lobar 9 (6) 2 (4) 0.586
Interstitial 42 (27) 13 (25) 0.767
Bilateral involvement 49 (32) 17 (33) 0.885
Days to starting oseltamivir
after disease onset, mean  SD
2.6  2 3  2 0.386
Secondary bacterial infection 3 (6) 7 (5) 0.715
Days from onset to hospital admission,
mean  SD
2.8  2.6 3  2.6 0.654
ICU stay 25 (16) 14 (27) 0.085
Use of invasive mechanical ventilation 19 (23) 9 (32) 0.33
Use of non-invasive mechanical ventilation 13 (14) 8 (25) 0.174
Length of hospital stay (days), mean  SD 8.5 (10) 7 (8.5) 0.329
Antibiotic use 95 (62) 34 (74) 0.141
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine
phosphokinase; CRP, C-reactive protein; ICU, intensive care unit; LDH, lactate
dehydrogenase; SD, standard deviation.
Table 3
Univariate and multivariate analyses for the predictors of mortality among the
adult inpatients.
Univariate analysis Multivariate analysis
OR 95% CI p-
Value
OR 95% CI p-Value
Age >65 years 6.3 2.63–
15.15
<0.001 6.9 2.07–
23.08
0.002
H3N2 vs. H1N1 4.3 1.81–
10.49
0.001 4.2 1.27–
14.38
0.019
One day delay of
oseltamivir
1.2 1.01–
1.39
0.032 1.3 1.01–
1.63
0.036
Secondary bacterial
infection
3.7 0.89–
15.35
0.07 2.8 0.4–
20.55
0.294
Presence of malignancy 3.5 1.14–
10.95
0.028 1.25 0.19–
8.22
0.811
OR, odds ratio; CI, conﬁdence interval.
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(SD 25) years, p = 0.005) (Table 2).
Thrombocyte counts were lower in the patients who died than
in the surviving patients (p < 0.004). The median alanine amino-
transferase (ALT), aspartate aminotransferase (AST), lactate dehy-
drogenase (LDH), creatine phosphokinase (CPK), and C-reactive
protein (CRP) levels were higher among fatal cases (Table 1).
Pulmonary ﬁndings were common among fatal cases, and theDownloaded for Anonymous User (n/a) at University of Queensland 
For personal use only. No other uses without permissionbilateral involvement rate was signiﬁcantly higher in these
patients than in those who survived (p < 0.001) (Table 2).
The mean number of days before the start of oseltamivir after
disease onset was higher among patients who died than among
those who survived; the difference was statistically signiﬁcant
(p = 0.025). A secondary bacterial infection was detected in three
(12%) fatal cases and seven (4%) surviving cases, with no
statistically difference between them (p = 0.055).
In total, 140 patients (65%) received antibiotics. The most
frequently ordered antibiotics were beta-lactams (41%), respirato-
ry ﬂuoroquinolones (20%), and macrolides (13%); 19% received
combined antibiotics. Among the patients who received anti-
biotics, only 6% had a suspected secondary bacterial infection. The
rate of vaccination against inﬂuenza A(H1N1) was 4%.
In the univariate analysis of the risk factors for mortality among
the adult inpatients, age (p < 0.001), being infected with A(H1N1)
or A(H3N2) (p = 0.001). In the multivariate logistic regression
model for the predictors of fatality among the adult inpatients,
being older than 65 years (odds ratio (OR) 6.9, 95% conﬁdence
interval (CI) 2.07–23.08, p = 0.002), being infected with inﬂuenza A
(H3N2) (OR 4.2, 95% CI 1.27–14.38, p = 0.019), and a 1-day delay in
antiviral use (OR 1.28, 95% CI 1.01–1.63, p = 0.036) signiﬁcantly
increased the likelihood of fatality (Table 3).
Discussion
This multicenter study involved 222 patients with laboratory-
conﬁrmed inﬂuenza A who were hospitalized in 11 hospitals in
Istanbul during the 2015–2016 season. The case fatality rate of
inﬂuenza A was high at 11.2% (Table 1). In the multivariate analysis,
age >65 years, being infected with inﬂuenza A(H3N2), and delayed
use of oseltamivir were found to be associated with fatality.
Approximately one-ﬁfth of the patients were over 65 years of age,
and no fatality occurred in those <16 years of age. It was also found
that adults with chronic heart and kidney diseases, chronic
neurological diseases, and malignancies were at increased risk of
greater disease severity and fatality. High rates of hospitalization
(Cox et al., 2012) and severe cases (Reed et al., 2014) have been
reported particularly in persons with underlying medical con-
ditions.
The morbidity and mortality associated with the A(H3N2) and A
(H1N1) subtypes of inﬂuenza were compared (Table 2). The fatality
rate for the patients infected with A(H3N2) was higher than that
for patients infected with A(H1N1) (OR 4.2, 95% CI 1.27–14.38,
p = 0.019; Table 3). In contrast, Chaves et al. reported that inﬂuenza
A(H1N1) caused more severe disease than inﬂuenza A(H3N2) or
inﬂuenza B in hospitalized patients (Chaves et al., 2013). In the
present study, patients hospitalized with inﬂuenza A(H1N1) were
younger than those hospitalized with inﬂuenza A(H3N2) (Table 2),
in parallel with previous reports (Reed et al., 2015; Minchole et al.,
2016). Minchole et al. reported that patients with inﬂuenza A
(H1N1) infection were younger, as found in the present study, but
that the virulence of inﬂuenza A(H1N1) was very high compared
with inﬂuenza A(H3N2) in hospitalized patients (Minchole et al.,
2016). The decreasing morbidity and mortality for inﬂuenza A
(H1N1) compared to inﬂuenza A(H3N2) could be explained by
changing immunity.
The unnecessary use of antimicrobial agents should be
emphasized. In this study, less than one in 10 patients had a
suspected secondary bacterial infection, but antibacterials were
ordered in nearly a quarter of the cases. One of the reasons for such
a high rate of unnecessary antibiotic use was because obtaining the
PCR test results in many centers requires an average of 2–3 days;
this conﬁrms a previous report from Turkey (Ergonul et al., 2014).
Early diagnosis of inﬂuenza virus infection will decrease the
unnecessary use of antibiotics. It is difﬁcult to consider bacterialLibrary from ClinicalKey.com.au by Elsevier on August 08, 2019.
. Copyright ©2019. Elsevier Inc. All rights reserved.
S. Tekin et al. / International Journal of Infectious Diseases 81 (2019) 6–9 9co-infection in some cases, such as pregnant women and
immunosuppressed patients or people over 65 years of age with
chronic diseases. This may be another reason for antibiotic use
even in those with positive inﬂuenza results.
Empiric oseltamivir treatment has been reported to be
beneﬁcial when inﬂuenza is suspected, even before conﬁrmed
laboratory results (Fiore et al., 2011). The results of the present
study emphasize the importance of the early use of oseltamivir, in
parallel with our ﬁndings during the inﬂuenza A pandemic
(Ergonul et al., 2014). Some studies have shown a reduction in
severe complications and mortality among inﬂuenza patients who
have received antivirals (Lee et al., 2010; Hiba et al., 2011). A study
from Denmark reported the failure of combined oral oseltamivir
and inhaled zanamivir in ventilator- and extracorporeal membrane
oxygenation (ECMO)-treated critically ill patients with pandemic
inﬂuenza A(H1N1) virus (Petersen et al., 2011).
In conclusion, the case fatality rate of inﬂuenza A(H3N2) was
signiﬁcantly higher than that of inﬂuenza A(H1N1). Early
detection of the infection, allowing the opportunity for the early
use of antiviral agents, was found to be important for the
prevention of death. Vaccination should be provided to at-risk
groups.
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